Search Results - "Prochetto, Estefanía"

Myeloid-derived suppressor cells and vaccination against pathogens by Prochetto, Estefanía, Borgna, Eliana, Jiménez-Cortegana, Carlos, Sánchez-Margalet, Víctor, Cabrera, Gabriel

“…It is widely accepted that the immune system includes molecular and cellular components that play a role in regulating and suppressing the effector immune…”
Get full text

Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection by Prochetto, Estefanía, Bontempi, Iván, Rodeles, Luz, Cabrera, Gabriel, Vicco, Miguel, Cacik, Paula, Pacini, María Florencia, Pérez Gianeselli, Mónica, Pérez, Ana Rosa, Marcipar, Iván

“…•A new vaccine formulation named TSNt-ISPA was developed against T. cruzi infection.•A therapeutic vaccine treatment was assessed in two chronic infection…”
Get full text

Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against Trypanosoma cruzi by Gamba, Juan Cruz, Roldán, Carolina, Prochetto, Estefanía, Lupi, Giuliana, Bontempi, Iván, Poncini, Carolina Verónica, Vermeulen, Mónica, Pérez, Ana Rosa, Marcipar, Iván, Cabrera, Gabriel

“…Trypanosoma cruzi ( T. cruzi ) is a hemoflagellate protozoan parasite that causes Chagas disease, a neglected tropical disease that affects more than 6 million…”
Get full text

Control of myeloid-derived suppressor cell dynamics potentiates vaccine protection in multiple mouse models of Trypanosoma cruzi infection by Borgna, Eliana, Prochetto, Estefanía, Gamba, Juan Cruz, Vermeulen, Elba Mónica, Poncini, Carolina Verónica, Cribb, Pamela, Pérez, Ana Rosa, Marcipar, Iván, González, Florencia Belén, Cabrera, Gabriel

“…To date, there is no licensed vaccine against the protozoan parasite Trypanosoma cruzi ( T. cruzi) , the etiological agent of Chagas Disease. T. cruzi has…”
Get full text

Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype by Quintana, Ingrid, Espariz, Martín, Villar, Silvina R, González, Florencia B, Pacini, Maria F, Cabrera, Gabriel, Bontempi, Iván, Prochetto, Estefanía, Stülke, Jörg, Perez, Ana R, Marcipar, Iván, Blancato, Victor, Magni, Christian

“…is a promising candidate for the development of mucosal vaccines. More than 20 years of experimental research supports this immunization approach. In addition,…”
Get full text

Increased epicardial adipose tissue thickness associated with increased metabolic risk and the presence of heart failure in patients with Chronic Chagas disease by Rodeles, Luz María, Castro, Maximiliano, Zamora, María Ayelen Gaitán, Savarino, Roberto, Peverengo, Luz María, Prochetto, Estefanía Soledad, Marcipar, Iván, Arias, Pablo, Vicco, Miguel Hernán

“…Abstract Background It has been described that Trypanosoma cruzi is capable of promoting metabolic disturbances currently considered as cardiovascular risk…”
Get full text

Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype by Prochetto, Estefanía, Roldán, Carolina, Bontempi, Iván A, Bertona, Daiana, Peverengo, Luz, Vicco, Miguel H, Rodeles, Luz M, Pérez, Ana R, Marcipar, Iván S, Cabrera, Gabriel

“…Prophylactic and/or therapeutic vaccines have an important potential to control ( )infection. The involvement of regulatory/suppressor immune cells after an…”
Get full text

Antibody profiles induced by Trypanosoma cruzi in chagasic patients with previous or current exposure to mycobacteria by Peverengo, Luz, Prochetto, Estefanía, Rodeles, Luz, Valenzuela, Ignacio, Marcipar, Iván Sergio, Bottasso, Oscar, Vicco, Miguel Hernán

“…Since the immune response mounted by the host to a particular microorganism might be influenced by the acquired immunological experience due to previous…”
Get full text

Role of myeloid-derived suppressor cells during Trypanosoma cruzi infection by Borgna, Eliana, Prochetto, Estefanía, Gamba, Juan Cruz, Marcipar, Iván, Cabrera, Gabriel

“…Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is the third largest parasitic disease burden globally. Currently, more than 6 million…”
Get full text

Simple protocol for measuring CD11b+ GR-1+ (Ly6C+/Ly6G+) myeloid cells from a minimum volume of mouse peripheral blood by Borgna, Eliana, Gamba, Juan Cruz, Prochetto, Estefanía, Marcipar, Iván, Cabrera, Gabriel

“…Myeloid-derived suppressor cells (MDSCs) comprise a heterogeneous population of myeloid origin and immature state, whose hallmark is the capacity to suppress T…”
Get full text

Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity by Pacini, María F., Balbi, Camila Bulfoni, Dinatale, Brenda, González, Florencia B., Prochetto, Estefania, De Hernández, María A., Cribb, Pamela, Farré, Cecilia, Espariz, Martín, Blancato, Víctor S., Magni, Christian, Marcipar, Iván, Pérez, Ana R.

“…Trypanosoma cruzi, the agent of Chagas disease, can infect through conjunctive or oral mucosas. Therefore, the induction of mucosal immunity by vaccination is…”
Get full text

Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi by Bontempi, Ivan, Fleitas, Pedro, Poato, Alexia, Vicco, Miguel, Rodeles, Luz, Prochetto, Estefania, Cabrera, Gabriel, Beluzzo, Bruno, Arias, Diego, Racca, Andrea, Guerrero, Sergio, Marcipar, Iván

“…The development of vaccines against Trypanosoma cruzi remains in an exploratory stage. Despite several antigen candidates have been evaluated, a comparison…”
Get full text

Trans-sialidase overcomes many antigens to be used as a vaccine candidate against by Bontempi, Ivan, Fleitas, Pedro, Poato, Alexia, Vicco, Miguel, Rodeles, Luz, Prochetto, Estefania, Cabrera, Gabriel, Beluzzo, Bruno, Arias, Diego, Racca, Andrea, Guerrero, Sergio, Marcipar, Iván

“…The development of vaccines against remains in an exploratory stage. Despite several antigen candidates have been evaluated, a comparison among the performance…”
Get full text